Skip to content
Home / News |

Co-Diagnostics Down 86% On $3.50 Worth Of Trades – Market Manipulation?

Key points:

  • The ticker has Co-Diagnostics down 86% this morning
  • The trigger here seems to be an entire $3.50 of trades
  • A mistake, maybe, possibly market manipulation

Co-Diagnostics (NASDAQ: CODX) stock is down 86.6% premarket on what looks suspiciously like a piece of market manipulation. Assuming that it’s not just some kids having some fun, or a fat finger mistake that is. For there’s absolutely no news to back up such a change in the CODX stock price, nothing out there at all. Also, the last trades at the end of yesterday’s session show no price movements anything like that. But at the opening of the premarket there were two trades of an entire $3.50 or so in total value – that’s all that it takes to drop the reported ticker by that 86%.

As to what our reaction should be well, try buying at this price. It’s not – for of course it’s not – an absolute certainty that there isn’t some gremlin in the system that we’ve not been told about as yet. But the bet would be, from my point of view, that this is someone playing with the reported price. As a result of that we’d expect, as the markets open and liquidity returns, the price to move back to somewhere close to last night’s close.

The problem with this as a plan is that while it might be entirely possible to sell as much CODX stock as we like at this price of $0.39, it’s going to be extraordinarily difficult to buy any at that price. Market makers might be willing to buy at below market but the idea that they’ll sell, in any volume, below it requires a certain amount of faith.

X testing X
WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
5.0
Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
Co-Diagnostics stock price
Co-Diagnostics stock price from IG

Also Read: Five Best Pharmaceutical Stocks to Watch in 2022

As we can see, there has been one recent collapse in the Co-Diagnostics stock price. So we might be primed to think that it can happen again. And yet look at this:

Co-Diagnostics trades
Co-Diagnostics trades from NASDAQ

And then this:

Co-Diagnostics premarket trades
Co-Diagnostics premarket trades from NASDAQ

OK, thinly traded stock and all of that. But if there were some disaster that gutted the CODX stock price then we’d not see total trade of perhaps $3.50 in value at this new $0.39 cents price. We’d see a flood of selling as a result of the disaster. So, the correct conclusion to draw here is that something like the postmarket price of $2 and change is correct, the $0.39 being the anomaly.

So, what do we think this is? It could, of course, be a fat finger mistake. Or some kids having fun – be a bit of a thing to brag about, moving a global price for $3. Or, possibly, someone out there has a derivatives position in CODX stock and they think they can close it out at a hugely manipulated price. My suspicion would be toward the third there, but I of course have no proof of it in this slightest – it’s a suspicion.

What should we do about it? Well, if it’s at all possible buy Co-Diagnostics at 39 cents and wait for the price to revert as the markets open and liquidity returns. But quite apart from the risk there – maybe there really is some news – I think the number of people willing to sell at 39 cents is going to be terribly small, likely to be no more than whoever it was who sold 9 pieces of stock earlier this morning.

Tim Worstall
Contributor

Tim Worstall is a freelance writer specialising in economics and the financial markets. He has written for most of the British press, from The Times to the Daily Sport, as well as the New York Times, Wall Street Journal, and Forbes.